Table 3.
Univariate and multivariate analyses of clinicopathological parameters in relation to PFS
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| miR-125b expression | 4.698 (2.326–6.547) | 0.006* | 4.573 (2.634–10.015) | <0.001* |
| Age (years) | 1.509 (0.647–2.265) | 0.368 | 1. 763 (0.936–2.217) | 0.508 |
| FIGO stage | 3.623 (1.684–4.374) | 0.031* | 3.017 (1.980–4.226) | 0.017* |
| HR-HPV | 3.632 (1.476–5.381) | 0.012* | 2.873 (1.560–4.735) | 0.006* |
| Differentiation | 1.780 (0.664–2.603) | 0.285 | 2.248 (0.905–3.144) | 0.483 |
| Tumor size | 1.682 (0.742–2.724) | 0.406 | 1.739 (0.804–3.225) | 0.452 |
| LN metastasis | 5.003 (2.052–10.024) | 0.037* | 4.108 (2.437–7.523) | 0.029* |
| Stromal invasion | 1.416 (0.725–2.683) | 0.285 | 1.436 (0.572–2.938) | 0.271 |
Note:
*
Significant correlation of clinicopathological parameters with PFS.
Abbreviations: FIGO, The International Federation of Gynecology and Obstetrics; HR-HPV, high-risk human papilloma virus; LN, lymph node; PFS, progression-free survival.